Overcoming Prior Authorization Barriers in LDL Cholesterol Therapies

Author(s):

Pam Taub, MD, FACC, FASPC,Michael Koren, MD, FACC

Michael Koren, MD addresses the challenges posed by prior authorization and the diminished role of pharmaceutical sales representatives in informing providers about medication advancements, leading to a disconnect in the provider's treatment arsenal.

EP: 1.Overview of Low-Density Lipoprotein Cholesterol Management

EP: 2.Stricter LDL-C Targets: Explaining Goalpost Changes to Patients

EP: 3.Ongoing Lp(a) Trials and Clinical Approaches to Treatment

EP: 4.Innovations in Small Interfering RNA (siRNA) Therapy

EP: 5.Optimizing PCSK9 Inhibitors and Analyzing Plaque Reduction Data

EP: 6.Evaluating Safety of Novel LDL Management Mechanism

EP: 7.Examining Results from VICTORION-INITIATE Trial

EP: 8.Other Notable Emerging Lipid-Lowering Treatments

EP: 9.REDUCE-IT Trial and Triglyceride-Lowering Agents

EP: 10.Diabetes, GLP-1, and Lipid Reduction

EP: 11.Medication Adherence in Patients with High LDL Cholesterol

Now Viewing

EP: 12.Overcoming Prior Authorization Barriers in LDL Cholesterol Therapies

EP: 13.Cardiometabolic Medicine: Seeing the Patient as a Whole

Video content above is prompted by the following questions:

How does your office handle payer approval/prior authorization for lipid lower medication? Are there any tips to help with getting approval?
How is help with co pay assistance programs coordinated in your practice to help increase accessibility and affordability?